Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.

Date publication

mai 2012

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie , Dr MOUILLET Guillaume

Tous les auteurs :
Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22722786

Résumé

Our study aimed to evaluate whether pathologic complete response (pCR) in early-stage non-small-cell lung cancer (NSCLC) after neoadjuvant chemotherapy resulted in improved outcome, and to determine predictive factors for pCR.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Non-Small-Cell Lung, drug therapy, Carcinoma, Squamous Cell, drug therapy, Chemotherapy, Adjuvant, Cisplatin, administration & dosage, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Female, Humans, Ifosfamide, administration & dosage, Lung Neoplasms, drug therapy, Male, Middle Aged, Mitomycin, administration & dosage, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Remission Induction, Survival Rate

Référence

J Thorac Oncol. 2012 May;7(5):841-9